title: Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
abstract: The enzyme DT-diaphorase (DTD; NAD(P)H:quinone oxidoreductase, EC 1.6.99.2), is an obligate two electron reductase which catalyzes reduction of a broad range of substrates, including quinones. We report here variations in DTD concentrations among different classes of lung tumors known also to vary in their responsiveness to cytotoxic agents. Small cell lung carcinomas (SCLCs) and cell lines derived from them have the low DTD activities and mRNA content characteristic of normal human lung, whereas non-small cell lung carcinomas (NSCLCs) have greatly elevated levels. DTD activity was increased up to 80-fold in NSCLC tumors relative to normal lung and 20-35-fold in NSCLC relative to SCLC cell lines. Increased DTD activity appeared to be a function of the NSCLC phenotype rather than a result of derivation from a cell type rich in DTD, since all histological classes of NSCLC showed this phenotype. In addition, where transfection of SCLC cell lines with the v-Ha-ras protooncogene caused a transition to a NSCLC phenotype, DTD activity was also elevated. Neuroendocrine-positive cells (SCLC, carcinoids, and a few NSCLC lines) typically had far lower DTD activities than did cell lines which lacked neuroendocrine markers (most NSCLC cells and mesotheliomas). High DTD activity may be exploited in the design of drugs which undergo bioreductive activation by this enzyme. Consistent with this, xenografts derived from NSCLC cell lines with high DTD that were grown in athymic nude mice were more susceptible to the antitumor quinone, mitomycin C, than were xenografts derived from SCLC cells containing low DTD. These data provide a mechanistic basis for the rational design of more effective bioreductive antitumor agents for use against NSCLC.
authors.affiliation: Molecular Toxicology and Environmental Health Sciences Program, University of Colorado, Boulder 80309.
authors.forename: A M
authors.initials: AM
authors.lastname: Malkinson
authors.forename: D
authors.initials: D
authors.lastname: Siegel
authors.forename: G L
authors.initials: GL
authors.lastname: Forrest
authors.forename: A F
authors.initials: AF
authors.lastname: Gazdar
authors.forename: H K
authors.initials: HK
authors.lastname: Oie
authors.forename: D C
authors.initials: DC
authors.lastname: Chan
authors.forename: P A
authors.initials: PA
authors.lastname: Bunn
authors.forename: M
authors.initials: M
authors.lastname: Mabry
authors.forename: D J
authors.initials: DJ
authors.lastname: Dykes
authors.forename: S D
authors.initials: SD
authors.lastname: Harrison
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology*; D018288:Carcinoma, Small Cell / Q000201:enzymology; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D051379:Mice; D008819:Mice, Nude; D016685:Mitomycin / Q000627:therapeutic use*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000235:genetics / Q000378:metabolism*; D009368:Neoplasm Transplantation; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured / Q000201:enzymology
chemical_list: D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016685:Mitomycin; D016660:NAD(P)H Dehydrogenase (Quinone)